API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ELZONRIS® (tagraxofusp), a recombinant protein is the only approved treatment for patients with blastic plasmacytoid dendritic cell neoplasm, and the first and only approved CD123-targeted therapy, in both the United States and Europe.
Lead Product(s): Tagraxofusp
Therapeutic Area: Oncology Product Name: Elzonris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nippon Shinyaku
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
ELZONRIS (tagraxofusp) is the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, in both the United States and Europe. Elzonris was originally developed by Stemline Therapeutics, now part of the Menarini Group.
Lead Product(s): Tagraxofusp
Therapeutic Area: Oncology Product Name: Elzonris
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Menarini
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 29, 2021
Details:
ELZONRIS is the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, in Europe. Approval is based on the results of the largest prospective clinical trial ever conducted in patients with treatment-naïve or previously-treated BPDCN.
Lead Product(s): Tagraxofusp
Therapeutic Area: Oncology Product Name: Elzonris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2021
Details:
Acquisition establishes Menarini’s presence in the U.S. biopharmaceutical oncology market. Menarini will support further development of Stemline’s ELZONRIS and enable global expansion by leveraging its commercial infrastructure in Europe and other ex-U.S. geographies.
Lead Product(s): Tagraxofusp
Therapeutic Area: Oncology Product Name: Elzonris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: $677.0 million Upfront Cash: $677.0 million
Deal Type: Acquisition June 10, 2020
Details:
With the support of Menarini’s infrastructure, Stemline will continue its efforts to develop new applications of ELZONRIS to meet unmet needs of patients with difficult to treat diseases and cancers.
Lead Product(s): Tagraxofusp
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: $677.0 million Upfront Cash: $677.0 million
Deal Type: Acquisition May 04, 2020
Details:
A Phase 1/2 trial of ELZONRIS in combination with other agents in patients with relapsed/refractory AML, treatment-naive AML unfit for chemotherapy, and high-risk myelodysplastic syndrome (MDS) is currently enrolling patients.
Lead Product(s): Tagraxofusp
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2020